drugset / Trial / NCT06916793
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia
Timeline
- Start
- 2025-04-08
- Primary completion
- 2027-09-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CKD-843 | Unknown | — | Intramuscular |
| Comparator | Dutasteride | Small molecule | — | Oral |